Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
The latest announcement is out from Sino Biopharmaceutical ( (HK:1177) ).
Sino Biopharmaceutical Limited has announced promising preliminary data from its phase I clinical study of TQB2102, a novel bispecific anti-HER2 antibody-drug conjugate, presented at the 2025 ASCO Annual Meeting. The study showed significant efficacy in treating various HER2-related cancers, including breast, colorectal, and gastric cancers, with a favorable safety profile compared to existing treatments. The ongoing phase III trials of TQB2102 are expected to potentially transform the treatment landscape for HER2 ADCs, offering a new therapeutic option with a lower incidence of adverse effects.
The most recent analyst rating on (HK:1177) stock is a Buy with a HK$7.00 price target. To see the full list of analyst forecasts on Sino Biopharmaceutical stock, see the HK:1177 Stock Forecast page.
More about Sino Biopharmaceutical
Sino Biopharmaceutical Limited is a company incorporated in the Cayman Islands, focusing on the biopharmaceutical industry. It is involved in the development and commercialization of innovative drugs, particularly in the field of oncology, with a market focus on advanced solid tumors and HER2-related cancers.
Average Trading Volume: 103,761,165
Technical Sentiment Signal: Buy
Current Market Cap: HK$74.8B
See more data about 1177 stock on TipRanks’ Stock Analysis page.